{"id":"triptorelin-recombinant-lh","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Abdominal pain/discomfort"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1200554","moleculeType":"Protein","molecularWeight":"1699.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triptorelin binds to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH secretion. When used in assisted reproductive technology (ART), this initial stimulation triggers the final maturation of oocytes and prepares the reproductive system for egg retrieval. The recombinant LH component provides exogenous luteinizing hormone to support follicle development and steroidogenesis during controlled ovarian stimulation.","oneSentence":"Triptorelin is a GnRH agonist that stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to support reproductive function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:41.787Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Controlled ovarian stimulation in assisted reproductive technology (ART) / in vitro fertilization (IVF)"}]},"trialDetails":[{"nctId":"NCT07128394","phase":"NA","title":"Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","status":"RECRUITING","sponsor":"Nanjing University","startDate":"2024-02-01","conditions":"Infertility, Female, Luteinizing Hormone (LH)","enrollment":590},{"nctId":"NCT00702520","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04-01","conditions":"Pregnancy, Neonates","enrollment":15},{"nctId":"NCT05567731","phase":"NA","title":"Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-15","conditions":"Intracytoplasmic Sperm Injection, GnRH Agonist, Infertility","enrollment":30},{"nctId":"NCT02625532","phase":"NA","title":"Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles (LUTEAL Trial)","status":"UNKNOWN","sponsor":"Instituto Bernabeu","startDate":"2015-12","conditions":"Reproductive Techniques, Assisted","enrollment":60},{"nctId":"NCT03118830","phase":"PHASE4","title":"Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-04-21","conditions":"Invitro Fertilization","enrollment":204},{"nctId":"NCT02979886","phase":"NA","title":"Effects of SNP of GnRH Receptor Genes in IVF Patients","status":"UNKNOWN","sponsor":"Miao benyu","startDate":"2017-01","conditions":"Infertility, Female","enrollment":1500},{"nctId":"NCT01500863","phase":"PHASE4","title":"Endometrial Receptivity After GnRH Agonist Triggering","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2011-11","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":35},{"nctId":"NCT01206803","phase":"","title":"Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2010-09","conditions":"Infertility, Subfertility","enrollment":294},{"nctId":"NCT02201914","phase":"PHASE4","title":"Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF","status":"UNKNOWN","sponsor":"Bioroma","startDate":"2014-01","conditions":"Poor Responders, IVF, Clomiphene Citrate","enrollment":250},{"nctId":"NCT01926210","phase":"PHASE4","title":"Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders","status":"UNKNOWN","sponsor":"Huang Rui","startDate":"2013-09","conditions":"Infertility","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"triptorelin, recombinant LH","genericName":"triptorelin, recombinant LH","companyName":"IVI Madrid","companyId":"ivi-madrid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triptorelin is a recombinant gonadotropin-releasing hormone (GnRH) agonist, classified as an AGONIST. It acts by binding to the gonadotropin-releasing hormone receptor, a protein, to modulate its activity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}